Determinants of Response to Talazoparib in Patients with HER2-negative, Germline BRCA1/2-mutated Breast Cancer.
Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martín M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA.
Clin Cancer Res. 2022 Jan 28:clincanres.2080.2021. doi: 10.1158/1078-0432.CCR-21-2080. Epub ahead of print.
Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Ozgüroglu M,Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J.
Clin Cancer Res. 2022 Jan 26. doi: 10.1158/1078-0432.CCR-21-3940. Epub ahead of print.